Linghag, Ariel O.
HRN: 17-12-07 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/27/2024
CO-AMOXICLAV 625MG (TAB)
06/27/2024
07/04/2024
PO
625/tab
Q8hrs
Multiple Wounds On Face And Extremities
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes